The antiaging properties of metformin used for the treatment of type-2 diabetes mellitus have been studied extensively, but there is more to discover regarding underlying mechanisms. Here, we show that metformin significantly prolongs the chronological lifespan (CLS) of Schizosaccharomyces pombe through mechanisms similar to those observed in mammalian cells and other model organisms. While the presence of metformin in the medium caused an increase in carbohydrate consumption and ATP production, it reduced reactive oxygen species production and alleviate oxidative damage parameters such as lipid peroxidation and carbonylated proteins. We also tested whether the effect of metformin changed with the time it was added to the medium and observed that the lifespan-prolonging effect of metformin was related to the glucose concentration in the medium and did not prolong lifespan when added after glucose was completely depleted in the medium. On the other hand, cells inoculated in glucose-free medium containing metformin also showed extended lifespan suggesting that mechanisms other than that solely depend on glucose availability may be involved in extending the lifespan. These results suggest that metformin prolongs lifespan especially affecting energy metabolism and stress resistance capacity and that fission yeast can be effectively used when investigating the antiaging mechanisms of metformin.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103822 | PMC |
http://dx.doi.org/10.1093/femsyr/foad018 | DOI Listing |
Front Endocrinol (Lausanne)
January 2025
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Background: The combination of cardiovascular disease and diabetes is a highly prevalent condition in the United Arab Emirates. Development and dissemination of evidence-based regional recommendations for optimal screening, treatment and referrals of people with diabetes and high cardiovascular risk is an important priority.
Consensus Panel: An expert panel of diabetologists, endocrinologists and cardiologists from the Emirates Cardiac Society and Emirates Diabetes and Endocrine Society as well as different entities in the UAE, discussed and reviewed evidence and also a consensus report from the American Diabetes Association to formulate contextualized recommendations that could be applied for optimal management of cardiovascular risk in people with diabetes in the UAE.
Front Endocrinol (Lausanne)
January 2025
Boston College, William F. Connell School of Nursing, Boston, MA, United States.
Background: The effect of antidiabetic agents on mortality outcomes is unclear for individuals with diabetes mellitus (DM) who are hospitalized for COVID-19.
Purpose: To examine the relationship between antidiabetic agent use and clinical outcomes in individuals with DM hospitalized for COVID-19.
Methods: A systematic review of the literature (2020-2024) was performed across five databases.
Indian J Clin Biochem
January 2025
College of Nursing, Al-Kitab University, Kirkuk, Iraq.
Adrenal insufficiency (AI) is a serious disorder characterized by the adrenal glucocorticoid deficiency. Regardless of the etiology, AI patients need long-term replacement therapy for glucocorticoids and, in some cases, for mineralocorticoids. The replacement therapy cannot completely mirror the physiological secretion patterns, and therefore, glucocorticoid excess is a common sequela in AI patients.
View Article and Find Full Text PDFInt J Nanomedicine
January 2025
Department of Pharmaceutical Sciences, School of Pharmacy, Lebanese American University, Byblos, Lebanon.
Introduction: Androgenetic alopecia (AGA) is a multifactorial and age-related dermatological disease that affects both males and females, usually at older ages. Traditional hair repair drugs exemplified by minoxidil have limitations such as skin irritation and hypertrichosis. Thus, attention has been shifted to the use of repurposing drugs.
View Article and Find Full Text PDFCureus
December 2024
Diabetes and Endocrinology, Arishina Life Sciences, Karnataka, IND.
Introduction: This study evaluated the effectiveness, safety, and tolerability of F-Biotic™ (Arishina Life Sciences, Karnataka, IND), a prebiotic containing 60% resistant starch derived from natural sources, in patients with Type 2 diabetes mellitus (T2DM) on stable metformin therapy.
Methods: Seventy participants with T2DM, aged 25-70 years, were randomized into two groups: one receiving F-Biotic™ and the other a placebo, both administered daily for 12 weeks. Key outcomes included fasting blood sugar (FBS), postprandial blood sugar (PPBS), glycated hemoglobin (HbA1c), fasting insulin, insulin resistance (HOMA-IR), GLP-1 levels, lipid profile, and quality of life.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!